In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Rima Fawaz about the role of GLP-1 receptor agonists in the treatment of children and adolescents with metabolic dysfunction-associated steatotic liver disease or MASLD (the artist formerly known as non-alcoholic fatty liver disease or NAFLD). We discuss what these medications do, what we know about their positive and negative effects, and how we should be using them based on the current literature. Dr. Fawaz is Medical Director of Pediatric Hepatology and Liver Transplantation at Yale New Haven Children's Hospital and Associate Professor at Yale School of Medicine.

Learning Objectives:

1. Understand the therapeutic and potential adverse effects of GLP-1 receptor agonists.
2. Recognize that the foundation of obesity and MASLD treatment remains lifestyle changes focused on diet and exercise.
3. Recognize the role that GLP-1 receptor agonists will play in our care for children and adolescents with obesity and MASLD.

Links:

Abou Jaoudeh RAR, et al. Pharmacological management of pediatric metabolic dysfunction-associated liver disaese. J Pediatr Gastroenterol Nutr. 2025.

Support the show

This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!

As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.

Check out our merch website!

Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.

Click here to support the show.

In this new episode Drs. Jason Silverman and Temara Hajjat sit down with Dr. Michael Dolinger to review intestinal ultrasound and how it will transform how we care for children with inflammatory bowel disease.

Michael Dolinger, MD, is the Director of Pediatric Inflammatory Bowel Disease and an Assistant Professor of Pediatrics at NYU Grossman School of Medicine. During his fellowship training, Dr. Dolinger became the first gastroenterology fellow in the United States to be trained and certified to perform intestinal ultrasound for inflammatory bowel disease activity monitoring. He has co-founded the Intestinal Ultrasound Group of the United States and Canada (iUSCAN) and now leads global training, education, and research efforts on the use of intestinal ultrasound as a non-invasive monitoring tool in inflammatory bowel disease care.

Learning objectives

1. Review the role for intestinal ultrasound in the diagnosis and monitoring of inflammatory bowel disease in children including its strengths and weaknesses.
2. Discuss the training path to certification in intestinal ultrasound.
3. Review strategies and considerations for integrating intestinal ultrasound into pediatric gastroenterology clinics.

Episode links

1. IUS as a pre-screening tool in clinical trials
2. IUS guide to billing and credentialing
3. IUS to predict endoscopic healing in children with CD
4. iUSscan.org

Support the show

This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!

As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.

Check out our merch website!

Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.

Click here to support the show.

In this episode, hosts Drs. Temara Hajjat and Jenn Lee talk to Dr. Rachel Chevalier. Dr. Chevalier is a pediatric gastroenterologist and physician scientist at Children's Mecy Hospital. She is an Associate Professor at the University of Missouri-Kansas City School of Medicine. In this episode, we’ll explore treatment options for eosinophilic esophagitis, discuss steroid complications and emerging therapies, and dive into the role of drug metabolism and genetics in optimizing patient care.

Learning Objectives:

• Discuss available corticosteroid options, dosing strategies, administration techniques, and challenges like insurance coverage and FDA limitations.
• Highlight potential complications of steroid use, mitigation strategies, and emerging treatments like orodispersible tablets.
• Explain the role of CYP enzymes, genetic variability, and personalized approaches to optimize treatment based on Dr. Rachel Chevalier’s research.

Support the show

This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!

As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.

Check out our merch website!

Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.

Click here to support the show.